Drug

anatlas Pharmaceuticals Doses First Patient in Phase II Trial of DAT‑2645 – Novel Targeted Therapy for BRCA‑Mutant, HRD‑Positive Ovarian Cancer
Clinical trial approval / initiationDanatlas Pharmaceuticals

Danatlas Pharmaceuticals Doses First Patient in Phase II Trial of DAT‑2645 – Novel Targeted Therapy for BRCA‑Mutant, HRD‑Positive Ovarian Cancer

Danatlas Pharmaceuticals announced that the first subject has been enrolled and dosed in the Phase II clinical study of DAT‑2645, the company's independently developed Class 1 innovative drug, at the…

Danatlas Pharmaceuticals Wins NMPA IND Approval for DAT‑6618 – China's First PPARγ Inhibitor to Enter Clinical Development

Danatlas Pharmaceuticals Wins NMPA IND Approval for DAT‑6618 – China’s First PPARγ Inhibitor to Enter Clinical Development

CSPC to Unveil Data From 8 Oncology Trials at ESMO Congress 2026 – Anbenitamab Phase III Results Headline Two Late‑Breaking Abstracts

CSPC to Unveil Data From 8 Oncology Trials at ESMO Congress 2026 – Anbenitamab Phase III Results Headline Two Late‑Breaking Abstracts

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
Sanofi's Wayrilz (Rilzabrutinib) Secures Japanese Approval for Immune Thrombocytopenia – Expanding Global Footprint Across Six Major Markets
NASDAQ: SNYProduct approvals

Sanofi’s Wayrilz (Rilzabrutinib) Secures Japanese Approval for Immune Thrombocytopenia – Expanding Global Footprint Across Six Major Markets

CancerClinical trial approval / initiation

Mabwell Secures NMPA Clinical Trial Approval for 6MW5311 Bispecific Antibody – Dual US-China Authorization for Hematological Malignancies

Ab&B Bio-TechClinical trial approval / initiation

Ab&B Bio-Tech Secures NMPA Clinical Trial Approval for mRNA Mpox Vaccine – First Dual-Approved Candidate Globally

China Medical SystemHKG: 0867

China Medical System’s Silvemimab Becomes World’s First Dual-Epitope Fully Human Rabies Antibody Approved in China

Show More